• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中国南方非小细胞肺癌患者的驱动基因改变及其与临床病理特征的相关性。

Driver gene alterations in NSCLC patients in southern China and their correlation with clinicopathologic characteristics.

作者信息

Deng Lingna, Li Jinbang, Qiu Zhanlong, Wang Yanfen

机构信息

Department of Pathology, The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, China.

出版信息

Front Genet. 2024 Sep 19;15:1455502. doi: 10.3389/fgene.2024.1455502. eCollection 2024.

DOI:10.3389/fgene.2024.1455502
PMID:39364008
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11446855/
Abstract

INTRODUCTION

In this study, we aimed to explore the relationship between clinicopathological features and driver gene changes in Chinese NSCLC patients.

METHODS

Amplification refractory mutation system PCR was used to detect the aberrations of 10 driver oncogenes in 851 Chinese NSCLC patients, and their correlation with clinicopathological characteristics was also analyzed. Moreover, three models of logistic regression were used to analyze the association between histopathology and or mutations.

RESULTS

The top two most frequently aberrant target oncogenes were (48.06%) and (9.51%). These were followed by (5.41%), (2.35%), (2.23%), (2.11%), (1.88%), (0.47%), (0.24%), and (0.12%). Additionally, 11 (1.29%) patients had synchronous gene alterations in two genes. The main mutations were exon 21 L858R and exon 19-Del, which accounted for 45.97% and 42.79% of all mutations, respectively. Logistic regression analysis showed that the frequency of mutations was positively correlated with women, non-smokers, lung adenocarcinoma, and invasive non-mucinous adenocarcinoma (IA), and negatively correlated with solid nodule, micro-invasive adenocarcinoma, and solid-predominant adenocarcinoma. mutations were positively associated with men and longer tumor long diameters and negatively correlated with lung adenocarcinoma ( for all).

CONCLUSION

Our findings suggest that the mutation frequency was higher in women, non-smokers, lung adenocarcinoma, and the IA subtype in lung adenocarcinoma patients, while the mutation rate was higher in men and patients with longer tumor long diameter and lower in lung adenocarcinoma patients.

摘要

引言

在本研究中,我们旨在探讨中国非小细胞肺癌(NSCLC)患者的临床病理特征与驱动基因变化之间的关系。

方法

采用扩增阻滞突变系统PCR检测851例中国NSCLC患者中10种驱动癌基因的畸变情况,并分析其与临床病理特征的相关性。此外,使用三种逻辑回归模型分析组织病理学与突变之间的关联。

结果

最常发生畸变的前两个靶癌基因为(48.06%)和(9.51%)。其次是(5.41%)、(2.35%)、(2.23%)、(2.11%)、(1.88%)、(0.47%)、(0.24%)和(0.12%)。此外,11例(1.29%)患者存在两个基因的同步基因改变。主要的突变是外显子21 L858R和外显子19缺失,分别占所有突变的45.97%和42.79%。逻辑回归分析显示,突变频率与女性、非吸烟者、肺腺癌和浸润性非黏液腺癌(IA)呈正相关,与实性结节、微浸润腺癌和实性为主型腺癌呈负相关。突变与男性和较长的肿瘤长径呈正相关,与肺腺癌呈负相关(所有情况均如此)。

结论

我们的研究结果表明,女性、非吸烟者、肺腺癌患者以及肺腺癌患者中的IA亚型的突变频率较高,而男性和肿瘤长径较长的患者的突变率较高,在肺腺癌患者中较低。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d78/11446855/e315b7b63394/fgene-15-1455502-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d78/11446855/ea1b85cc4a3d/fgene-15-1455502-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d78/11446855/e315b7b63394/fgene-15-1455502-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d78/11446855/ea1b85cc4a3d/fgene-15-1455502-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0d78/11446855/e315b7b63394/fgene-15-1455502-g002.jpg

相似文献

1
Driver gene alterations in NSCLC patients in southern China and their correlation with clinicopathologic characteristics.中国南方非小细胞肺癌患者的驱动基因改变及其与临床病理特征的相关性。
Front Genet. 2024 Sep 19;15:1455502. doi: 10.3389/fgene.2024.1455502. eCollection 2024.
2
[Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].非小细胞肺癌临床病理特征与驱动基因突变的相关性
Zhonghua Bing Li Xue Za Zhi. 2016 Apr 8;45(4):221-5. doi: 10.3760/cma.j.issn.0529-5807.2016.04.002.
3
Status of 10 targeted genes of non-small cell lung cancer in eastern China: A study of 884 patients based on NGS in a single institution.中国东部 884 例患者基于单中心 NGS 的 10 个非小细胞肺癌靶向基因检测分析
Thorac Cancer. 2020 Sep;11(9):2580-2589. doi: 10.1111/1759-7714.13577. Epub 2020 Jul 30.
4
[Correlation between common driver gene variations and clinicopathological typing in lung adenocarcinoma].[肺腺癌中常见驱动基因变异与临床病理分型的相关性]
Zhonghua Bing Li Xue Za Zhi. 2024 Jun 8;53(6):578-584. doi: 10.3760/cma.j.cn112151-20231019-00277.
5
Comprehensive molecular analysis of driver mutations in non-small cell lung carcinomas and its correlation with PD-L1 expression, An Indian perspective.非小细胞肺癌中驱动基因突变的全面分子分析及其与 PD-L1 表达的相关性:印度视角。
Pathol Res Pract. 2024 Jan;253:155013. doi: 10.1016/j.prp.2023.155013. Epub 2023 Dec 6.
6
Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.1321例中国肺腺癌患者中11个靶基因的异常状态及临床病理特征相关性
J Thorac Dis. 2018 Jan;10(1):398-407. doi: 10.21037/jtd.2017.12.68.
7
Correlative analysis of gene mutation and clinical features in patients with non-small cell lung cancer.非小细胞肺癌患者基因突变与临床特征的相关性分析
Transl Cancer Res. 2019 Jun;8(3):736-751. doi: 10.21037/tcr.2019.04.10.
8
Analysis of multigene detection in patients with advanced lung adenocarcinoma using cytological specimens.使用细胞学标本对晚期肺腺癌患者进行多基因检测分析。
Pathol Res Pract. 2020 Aug;216(8):153036. doi: 10.1016/j.prp.2020.153036. Epub 2020 May 28.
9
Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.基于下一代测序的肺癌分子诊断特征及其与 PD-L1 表达的关系。
Pathol Res Pract. 2020 Feb;216(2):152797. doi: 10.1016/j.prp.2019.152797. Epub 2019 Dec 23.
10
Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.中国非小细胞肺癌中靶向下一代测序鉴定的驱动基因的基因组特征。
Oncologist. 2019 Nov;24(11):e1070-e1081. doi: 10.1634/theoncologist.2018-0572. Epub 2019 Mar 22.

本文引用的文献

1
Lung cancer treatment: 20 years of progress.肺癌治疗:20年的进展
Lancet. 2024 Jun 22;403(10445):2663. doi: 10.1016/S0140-6736(24)01299-6.
2
Alectinib in Resected -Positive Non-Small-Cell Lung Cancer.阿来替尼治疗可切除阳性非小细胞肺癌。
N Engl J Med. 2024 Apr 11;390(14):1265-1276. doi: 10.1056/NEJMoa2310532.
3
A Phase II trial of alternating osimertinib and gefitinib therapy in advanced EGFR-T790M positive non-small cell lung cancer: OSCILLATE.奥希替尼和吉非替尼交替治疗晚期 EGFR-T790M 阳性非小细胞肺癌的 II 期试验:OSCILLATE。
Nat Commun. 2024 Feb 28;15(1):1823. doi: 10.1038/s41467-024-46008-1.
4
Patients with uncommon EGFR mutations also benefit from first-line osimertinib.具有罕见表皮生长因子受体(EGFR)突变的患者也能从一线使用奥希替尼中获益。
Nat Rev Clin Oncol. 2024 Feb;21(2):84. doi: 10.1038/s41571-023-00847-x.
5
Osimertinib with or without Chemotherapy in -Mutated Advanced NSCLC.奥希替尼对比含铂化疗用于 - 突变型晚期 NSCLC。
N Engl J Med. 2023 Nov 23;389(21):1935-1948. doi: 10.1056/NEJMoa2306434. Epub 2023 Nov 8.
6
Survival analysis of patients with advanced non-small cell lung cancer receiving EGFR-TKI treatment of Yunnan in southwestern China: a real-world study.中国西南部云南省晚期非小细胞肺癌患者接受表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKI)治疗的生存分析:一项真实世界研究
Front Oncol. 2023 Oct 10;13:1156647. doi: 10.3389/fonc.2023.1156647. eCollection 2023.
7
Osimertinib in Resected EGFR-Mutated NSCLC.奥希替尼用于可切除的表皮生长因子受体(EGFR)突变的非小细胞肺癌(NSCLC)
N Engl J Med. 2023 Oct 5;389(14):1341-1342. doi: 10.1056/NEJMc2309385.
8
A rare case of double primary lung adenocarcinomas with uncommon complex EGFR G719X and S768I mutations and pleomorphic carcinoma.罕见的双重原发性肺腺癌,具有罕见的复杂 EGFR G719X 和 S768I 突变以及多形性癌。
Thorac Cancer. 2023 Oct;14(29):2981-2984. doi: 10.1111/1759-7714.15085. Epub 2023 Aug 24.
9
Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations.比较第二代和第三代 TKI 治疗非小细胞肺癌罕见 EGFR 突变的疗效和安全性。
Cancer Med. 2023 Aug;12(15):15903-15911. doi: 10.1002/cam4.6229. Epub 2023 Jun 12.
10
Non-small cell lung cancer in China.中国的非小细胞肺癌。
Cancer Commun (Lond). 2022 Oct;42(10):937-970. doi: 10.1002/cac2.12359. Epub 2022 Sep 8.